ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study has been completed.

Sponsored by: Telik
Information provided by: Telik
ClinicalTrials.gov Identifier: NCT00080340
  Purpose

The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.


Condition Intervention Phase
Non Small Cell Lung Carcinoma
Drug: TLK286 (Telcyta) HCl for Injection
Drug: gefitinib (Iressa)
Phase III

MedlinePlus related topics:   Cancer    Lung Cancer   

Drug Information available for:   ZD1839   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:   Phase 3 Randomized Study of TLK286 (Telcyta) Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Further study details as provided by Telik:

Estimated Enrollment:   520
Estimated Study Completion Date:   May 2005

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Clinical diagnosis of non-small cell lung cancer
  • Non-small cell lung cancer that is not curable with surgery, radiation, or combined modality chemoradiation
  • Failed two prior chemotherapy regimens which must have included platinum
  • Measurable disease

Exclusion Criteria:

  • Treatment with more than two prior chemotherapy regimens
  • History of bone marrow transplantation or stem cell support
  • Pregnant or lactating women
  • Known history of prior gefitinib therapy
  • Known history of prior TLK286 therapy
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00080340

Show 345 study locations  Show 345 Study Locations

Sponsors and Collaborators
Telik
  More Information


Related Info  This link exits the ClinicalTrials.gov site
 

Study ID Numbers:   TLK286.3020
First Received:   March 26, 2004
Last Updated:   January 10, 2008
ClinicalTrials.gov Identifier:   NCT00080340
Health Authority:   United States: Food and Drug Administration

Study placed in the following topic categories:
Thoracic Neoplasms
Non-small cell lung cancer
Respiratory Tract Diseases
Lung Neoplasms
Lung Diseases
Gefitinib
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Carcinoma

Additional relevant MeSH terms:
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Therapeutic Uses
Enzyme Inhibitors
Protein Kinase Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 30, 2008




Links to all studies - primarily for crawlers